PL3294769T3 - Leczenie szpiczaka mnogiego (mm) - Google Patents

Leczenie szpiczaka mnogiego (mm)

Info

Publication number
PL3294769T3
PL3294769T3 PL16723349T PL16723349T PL3294769T3 PL 3294769 T3 PL3294769 T3 PL 3294769T3 PL 16723349 T PL16723349 T PL 16723349T PL 16723349 T PL16723349 T PL 16723349T PL 3294769 T3 PL3294769 T3 PL 3294769T3
Authority
PL
Poland
Prior art keywords
treatment
multiple myeloma
myeloma
Prior art date
Application number
PL16723349T
Other languages
English (en)
Inventor
Stéphane LECLAIR
Jan Endell
Stefan HÄRTLE
Original Assignee
Morphosys Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Morphosys Ag filed Critical Morphosys Ag
Publication of PL3294769T3 publication Critical patent/PL3294769T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0021—Intradermal administration, e.g. through microneedle arrays, needleless injectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Dermatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • Endocrinology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Magnetic Resonance Imaging Apparatus (AREA)
  • Display Devices Of Pinball Game Machines (AREA)
PL16723349T 2015-05-13 2016-05-13 Leczenie szpiczaka mnogiego (mm) PL3294769T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP15167597 2015-05-13
EP16723349.3A EP3294769B1 (en) 2015-05-13 2016-05-13 Treatment for multiple myeloma (mm)
PCT/EP2016/060810 WO2016180958A1 (en) 2015-05-13 2016-05-13 Treatment for multiple myeloma (mm)

Publications (1)

Publication Number Publication Date
PL3294769T3 true PL3294769T3 (pl) 2021-07-05

Family

ID=53174925

Family Applications (1)

Application Number Title Priority Date Filing Date
PL16723349T PL3294769T3 (pl) 2015-05-13 2016-05-13 Leczenie szpiczaka mnogiego (mm)

Country Status (24)

Country Link
US (2) US10533057B2 (pl)
EP (1) EP3294769B1 (pl)
JP (2) JP7160533B2 (pl)
KR (1) KR20180008571A (pl)
CN (1) CN107614530A (pl)
AU (1) AU2016260895B2 (pl)
CA (1) CA2984464C (pl)
CY (1) CY1123982T1 (pl)
DK (1) DK3294769T3 (pl)
ES (1) ES2862708T3 (pl)
HR (1) HRP20210552T1 (pl)
HU (1) HUE054271T2 (pl)
IL (1) IL255552B (pl)
LT (1) LT3294769T (pl)
MX (1) MX380557B (pl)
PL (1) PL3294769T3 (pl)
PT (1) PT3294769T (pl)
RS (1) RS61668B1 (pl)
RU (1) RU2723047C2 (pl)
SG (1) SG11201708691VA (pl)
SI (1) SI3294769T1 (pl)
SM (1) SMT202100202T1 (pl)
WO (1) WO2016180958A1 (pl)
ZA (1) ZA201708386B (pl)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JOP20210044A1 (ar) 2010-12-30 2017-06-16 Takeda Pharmaceuticals Co الأجسام المضادة لـ cd38
PL3294769T3 (pl) * 2015-05-13 2021-07-05 Morphosys Ag Leczenie szpiczaka mnogiego (mm)
CN109689690B (zh) 2016-07-15 2023-10-03 武田药品工业株式会社 用于评估对于成浆细胞和浆细胞耗竭性疗法的应答的方法和材料
CA3088199A1 (en) 2018-01-12 2019-07-18 Takeda Pharmaceutical Company Limited Subcutaneous dosing of anti-cd38 antibodies
CN110144008B (zh) * 2018-02-12 2021-03-19 杭州尚健生物技术有限公司 Cd38蛋白抗体及其应用
AU2019244478B2 (en) * 2018-03-28 2025-11-06 Takeda Pharmaceutical Company Limited Subcutaneous dosing of anti-CD38 antibodies
CN109265551B (zh) * 2018-09-25 2020-09-15 华东师范大学 Cd38抗体、嵌合抗原受体和药物
AU2019395841B2 (en) * 2018-12-14 2025-02-27 Morphosys Ag Antibody formulations
EP4588484A3 (en) * 2019-01-28 2025-10-15 Sanofi-Aventis U.S. LLC Methods of treating multiple myeloma
US20200308296A1 (en) * 2019-03-28 2020-10-01 Janssen Biotech, Inc. Clinically Proven Subcutaneous Pharmaceutical Compositions Comprising Anti-CD38 Antibodies and Their Uses in Combination with Pomalidomide and Dexamethasone

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020164788A1 (en) 1994-12-02 2002-11-07 The Wellcome Foundation Limited Humanized antibodies to CD38
CA2329940A1 (en) 1998-06-05 1999-12-09 Mayo Foundation For Medical Education And Research Use of genetically engineered antibodies to cd38 to treat multiple myeloma
EP1174440A1 (en) 2000-07-19 2002-01-23 U-BISys B.V. A selectively-expressed epitope on the human CD38 molecule detected by a phage display library-derived human scFv antibody fragment
SI2511297T1 (sl) 2004-02-06 2015-07-31 Morphosys Ag Proti -CD38 humana protitelesa in njihova uporaba
EP1720907B1 (en) 2004-02-06 2015-04-08 MorphoSys AG Anti-cd38 human antibodies and uses therefor
SG10201912554TA (en) 2005-03-23 2020-02-27 Genmab As Antibodies against cd38 for treatment of multiple myeloma
TW200745162A (en) 2005-05-24 2007-12-16 Morphosys Ag Generation and profiling of fully human hucal gold-derived therapeutic antibodies specific for human CD38
CN103554260A (zh) 2005-10-12 2014-02-05 莫佛塞斯公司 特异性针对人CD38的完全人HuCAL GOLD-衍生治疗抗体的生成和鉴定
EP2641601B8 (en) * 2006-08-07 2016-09-21 AbbVie Biotherapeutics Inc. Methods of treating multiple myeloma using combination therapies based on HuLuc63 with bortezomib
PL2081595T3 (pl) * 2006-09-26 2019-11-29 Genmab As Anty-cd38 wraz z kortykosteroidami wraz ze środkiem chemioterapeutycznym niebędącym kortykosteroidem, do leczenia guzów nowotworowych
EP1914242A1 (en) 2006-10-19 2008-04-23 Sanofi-Aventis Novel anti-CD38 antibodies for the treatment of cancer
EP2580243B1 (en) * 2010-06-09 2019-10-16 Genmab A/S Antibodies against human cd38
BR112013006769B1 (pt) * 2010-09-27 2021-02-02 Morphosys Ag combinação sinérgica
WO2014089279A1 (en) * 2012-12-05 2014-06-12 H. Lee Moffitt Cancer Center And Research Institute, Inc. Rnf41 as a biomarker predicting response to lenalidomide in non-del(5q) mds
CN103421115B (zh) * 2013-09-02 2015-06-03 东南大学 一种cd38纳米抗体及应用
JP6600651B2 (ja) 2014-06-16 2019-10-30 マヨ ファウンデーション フォー メディカル エデュケーション アンド リサーチ 骨髄腫の治療
MA39070A1 (fr) * 2014-07-31 2017-11-30 Sanofi Sa Anticorps anti-cd38 spécifiques pour le traitement de cancers humains
US10617757B2 (en) * 2014-08-08 2020-04-14 The Regents Of The University Of California Methods for treating multiple myeloma
EA035979B1 (ru) 2014-09-09 2020-09-08 Янссен Байотек, Инк. Варианты комбинированной терапии анти-cd38 антителами
PL3294769T3 (pl) * 2015-05-13 2021-07-05 Morphosys Ag Leczenie szpiczaka mnogiego (mm)

Also Published As

Publication number Publication date
RS61668B1 (sr) 2021-04-29
PT3294769T (pt) 2021-04-13
AU2016260895B2 (en) 2021-08-05
ES2862708T3 (es) 2021-10-07
MX2017014396A (es) 2018-03-23
RU2723047C2 (ru) 2020-06-08
ZA201708386B (en) 2019-06-26
WO2016180958A1 (en) 2016-11-17
US20200079871A1 (en) 2020-03-12
MX380557B (es) 2025-03-12
CA2984464A1 (en) 2016-11-17
RU2017137496A3 (pl) 2019-06-13
CN107614530A (zh) 2018-01-19
SI3294769T1 (sl) 2021-07-30
RU2017137496A (ru) 2019-06-13
IL255552A (en) 2018-01-31
SMT202100202T1 (it) 2021-05-07
US20190048091A1 (en) 2019-02-14
HRP20210552T1 (hr) 2021-05-14
JP2021130668A (ja) 2021-09-09
CA2984464C (en) 2023-10-10
SG11201708691VA (en) 2017-11-29
AU2016260895A1 (en) 2017-11-09
LT3294769T (lt) 2021-04-26
EP3294769B1 (en) 2021-01-13
IL255552B (en) 2022-01-01
US10533057B2 (en) 2020-01-14
US11591406B2 (en) 2023-02-28
DK3294769T3 (da) 2021-03-08
JP7160533B2 (ja) 2022-10-25
KR20180008571A (ko) 2018-01-24
JP2018515513A (ja) 2018-06-14
EP3294769A1 (en) 2018-03-21
HUE054271T2 (hu) 2021-08-30
CY1123982T1 (el) 2022-05-27

Similar Documents

Publication Publication Date Title
SG11201705093UA (en) Composition for treating il-6-related diseases
GB2544294B (en) Goggles for snowsports
ZA201708386B (en) Treatment for multiple myeloma (mm)
IL278247B (en) mct4 inhibitors to treat the disease
GB201500989D0 (en) Process
GB201502894D0 (en) Process
IL256116B (en) geometric
IL254393A0 (en) Methods for treating diseases associated with pathological changes in protein
GB201502137D0 (en) Treatment
GB201502893D0 (en) Process
GB201522243D0 (en) Treatment
GB201501952D0 (en) Process
GB201501953D0 (en) Process
GB201500990D0 (en) Process
GB201501423D0 (en) Process
GB201519450D0 (en) Novel treatment
GB201502814D0 (en) Process
GB201604658D0 (en) Treatment for pain
GB201519331D0 (en) Treatment paradigm
GB201508841D0 (en) Treatment
GB201503606D0 (en) Process
PT3350149T (pt) Compostos terminados com[(2-etoxi-5-trans-1-propen-1-il)-fenoxil]
SG11201706885RA (en) Novel treatment method
GB201503008D0 (en) Treatment
GB201500277D0 (en) Process